Heres our nearest rival noticing a 15% lift in sales off the back of our launch marketing.. imagine what its doing to our numbers? Strap in.
Earnings call transcript: Journey Medical Q1 2025 reports revenue beat
In reference to QBREXZA, we are extremely pleased with how the product performance continues to be. As you’re well aware, a competitor came out to QBREXZA called Softra. They started their launch back in January of this year. They have a full sales force and they’re working on their telemedicine platform.
We are looking at prescriptions all the way through March and we actually just got prescriptions of April as of today..And what we’re seeing is exactly what we had expected. Softron and botanics is bringing more awareness to the disease state of primary axillary hyperhidrosis. And we are benefiting, I believe, from that, including what our marketing and commercial team is doing.
So for example, in March, we were 15% above in prescriptions compared to last year, twenty twenty four March. And I’m pleased to say in April, again, hot off the presses, we continue to see a 15% growth month over month when you look at April 2025 versus April 2024.
(20min delay)